Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy

Clinica Chimica Acta

Volumn 411, Issue 7-8, 2010, Pages 581-583

  Wang, Liang ^a   Pan, Yumin ^a   Chen, Dan ^a   Xiao, Zheng ^a   Xi, Zhiqin ^a   Xiao, Fei ^a   Wang, Xuefeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Cerebrospinal fluid; ELISA; Epilepsy; Serum; Tetranectin

Indexed keywords

ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; TETRANECTIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHOOL CHILD; SEIZURE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CEREBROSPINAL FLUID; CHILD; EPILEPSY; FEMALE; HUMANS; LECTINS, C-TYPE; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 77649180953     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.01.022     Document Type: Article

References (31)

1. Clemmensen I., Petersen L.C., Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986, 156:327-333.
2. Holtet T.L., Graversen J.H., Clemmensen I., Thogersen H.C., Etzerodt M. Tetranectin, a trimeric plasminogen-binding C-type lectin. Protein Sci 1997, 6:1511-1515.
3. Berglund L., Petersen T.E. The gene structure of tetranectin, a plasminogen binding protein. FEBS Lett 1992, 309:15-19.
4. Christensen L., Clemmensen I. Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme. Histochemistry 1989, 92:29-35.
5. Iba K., Hatakeyama N., Kojima T., et al. Impaired cutaneous wound healing in mice lacking tetranectin. Wound Repair Regen 2009, 17:108-112.
6. Iba K., Sawada N., Chiba H., Wewer U.M., Ishii S., Mori M. Transforming growth factor-beta 1 downregulates dexamethasone-induced tetranectin gene expression during the in vitro mineralization of the human osteoblastic cell line SV-HFO. FEBS Lett 1995, 373:1-4.
7. Iba K., Durkin M.E., Johnsen L., et al. Mice with a targeted deletion of the tetranectin gene exhibit a spinal deformity. Mol Cell Biol 2001, 21:7817-7825.
8. Mogues T., Etzerodt M., Hall C., Engelich G., Graversen J.H., Hartshorn K.L. Tetranectin binds to the kringle 1-4 form of angiostatin and modifies its functional activity. J Biomed Biotechnol 2004, 2004:73-78.
9. Wewer U.M., Iba K., Durkin M.E., et al. Tetranectin is a novel marker for myogenesis during embryonic development, muscle regeneration, and muscle cell differentiation in vitro. Dev Biol 1998, 247-259.
10. De Vries T.J., De Wit P.E., Clemmensen I., et al. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions. J Pathol 1996, 179:260-265.
11. Verspaget H.W., Clemmensen I., Ganesh S., et al. Tetranectin expression in human colonic neoplasia. Histopathology 1994, 25:463-467.
12. Christensen L., Johansen N., Jensen B.A., Clemmensen I. Immunohistochemical localization of a novel, human plasma protein, tetranectin, in human endocrine tissues. Histochemistry 1987, 87:195-199.
13. Nielsen H., Clemmensen I., Kharazmi A. Tetranectin: a novel secretory protein from human monocytes. Scand J Immunol 1993, 37:39-42.
14. Stoevring B., Jaliashvili I., Thougaard A.V., et al. Tetranectin in cerebrospinal fluid: biochemical characterisation and evidence of intrathecal synthesis or selective uptake into CSF. Clin Chim Acta 2005, 359:65-71.
15. Hogdall C.K., Soletormos G., Nielsen D., Norgaard-Pedersen B., Dombernowsky P., Clemmensen I. Prognostic value of serum tetranectin in patients with metastatic breast cancer. Acta Oncol 1993, 32:631-636.
16. Hogdall C.K., Christiansen M., Norgaard-Pedersen B., Bentzen S.M., Kronborg O., Clemmensen I. Plasma tetranectin and colorectal cancer. Eur J Cancer 1995, 31A:888-894.
17. Arvanitis D.L., Kamper E.F., Kopeikina L., et al. Tetranectin expression in gastric adenocarcinomas. Histol Histopathol 2002, 17:471-475.
18. Blaakaer J., Hogdall C.K., Micic S., et al. Ovarian carcinoma serum markers and ovarian steroid activity-is there a link in ovarian cancer? A correlation of inhibin, tetranectin and CA-125 to ovarian activity and the gonadotropin levels. Eur J Obstet Gynecol Reprod Biol 1995, 59:53-56.
19. Kamper E.F., Papaphilis A.D., Angelopoulou M.K., et al. Serum levels of tetranectin, intercellular adhesion molecule-1 and interleukin-10 in B-chronic lymphocytic leukemia. Clin Biochem 1999, 32:639-645.
20. Deng X., Hogdall E.V., Hogdall C.K., et al. The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer. Gynecol Oncol 2000, 79:416-419.
21. Gronlund B., Hogdall E.V., Christensen I.J., et al. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int J Biol Markers 2006, 21:141-148.
22. Xiao F., Chen D., Lu Y., et al. Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy. Brain Res 2009, 1255:180-189.
23. Liu X.D., Zeng B.F., Xu J.G., Zhu H.B., Xia Q.C. Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics 2006, 6:1019-1028.
24. Hammack B.N., Fung K.Y., Hunsucker S.W., et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004, 10:245-260.
25. Stoevring B., Jaliashvili I., Thougaard A.V., et al. Tetranectin in cerebrospinal fluid of patients with multiple sclerosis. Scand J Clin Lab Invest 2006, 66:577-583.
26. Seino M. Classification criteria of epileptic seizures and syndromes. Epilepsy Res 2006, 70(Suppl 1):S27-33.
27. Dietzmann K., von Bossanyi P., Krause D., Wittig H., Mawrin C., Kirches E. Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: an immunohistochemical study. Pathol Res Pract 2000, 196:15-21.
28. Meldrum B.S. Excitotoxicity and selective neuronal loss in epilepsy. Brain Pathol 1993, 3:405-412.
29. Zhang S., Khanna S., Tang F.R. Patterns of hippocampal neuronal loss and axon reorganization of the dentate gyrus in the mouse pilocarpine model of temporal lobe epilepsy. J Neurosci Res 2009, 87:1135-1149.
30. Oby E., Janigro D. The blood-brain barrier and epilepsy. Epilepsia 2006, 47:1761-1774.
31. Rigau V., Morin M., Rousset M.C., et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain 2007, 130:1942-1956.